CN101830964A - Triterpenoid compounds with anti-inflammatory activities - Google Patents
Triterpenoid compounds with anti-inflammatory activities Download PDFInfo
- Publication number
- CN101830964A CN101830964A CN 201010179553 CN201010179553A CN101830964A CN 101830964 A CN101830964 A CN 101830964A CN 201010179553 CN201010179553 CN 201010179553 CN 201010179553 A CN201010179553 A CN 201010179553A CN 101830964 A CN101830964 A CN 101830964A
- Authority
- CN
- China
- Prior art keywords
- compound
- inflammatory
- compounds
- decompression
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of medicaments, and discloses seven new triterpenoid compounds with anti-inflammatory activities, which are extracted and separated from Chinese medicinal cherokee rose leaves. Through in vitro anti-inflammatory activity experiments, the compounds can remarkably inhibit luciferase expression caused by lipopolysaccharide (LPS) in 293-nfkb cells, present a dose dependency relationship and have obvious anti-inflammatory activities. Therefore, the compounds can be used for preparing new anti-inflammatory medicaments. The compounds provide new sources for preparing the anti-inflammatory medicaments.
Description
Technical field
The present invention relates to medical technical field, is 7 new triterpene compounds with anti-inflammatory activity that extraction separation obtains from the Chinese medicine Leaf of Cherokee Rose.
Background technology
Leaf of Cherokee Rose is the tender leaf of Rosaceae gul Fruit of Cherokee Rose (Rosa laevigata Michx.).It is very wide to distribute in China, mainly is distributed in areas such as East China, Central-South, southwest.Leaf of Cherokee Rose is a conventional Chinese medicine among the people, is one of main component of ancient prescription " children's indigestion powder in the army ", and it is hemorrhage to cure mainly metal-inflicted wound.From Leaf of Cherokee Rose, extracted triterpene compound urson, Jacaric acid, Rialic acid A, Oleanolic Acid, Crategolic acid, etc. triterpenic acid active component and Fruit of Cherokee Rose saponin A, Flos rosae multiflorae glycosides, Tormentic acid-28-O-β-triterpenoid saponin active components such as D-glucopyranoside, their chemical structure of general formula is as follows:
Wherein, R
1Expression hydrogen or hydroxyl, R
2Expression hydrogen or hydroxyl, R
3Expression hydrogen or glucopyranosyl, R
4Expression hydrogen or methyl, R
5Expression hydrogen or hydroxyl, R
6Expression hydrogen or methyl, R
7Expression methyl or methylol.But do not see the report that from Leaf of Cherokee Rose, separates 7 new triterpene compounds that obtain provided by the invention so far with anti-inflammatory activity.
Summary of the invention
The invention provides a kind of new 7 triterpene compounds with anti-inflammatory activity that obtain that separate from the Chinese medicine Leaf of Cherokee Rose, their chemical structural formula is as follows respectively:
Through the extracorporeal anti-inflammatory activity test, they all can significantly suppress luciferase expression in the 293-nfkb cell that lipopolysaccharides (LPS) causes, and present dose-dependence, show to have tangible anti-inflammatory activity.Therefore, can be used for preparing new anti-inflammatory drug.
The preparation method of The compounds of this invention is as follows:
1. prepare the Leaf of Cherokee Rose extract
The Chinese medicine Leaf of Cherokee Rose is used 40~95% aqueous ethanolic solution soaked overnight routinely, heating and refluxing extraction 2~3 times, each 1~3 hour, united extraction liquid, decompression and solvent recovery gets extract medicinal extract;
2. extraction triterpene compound
Medicinal extract is dissolved in water, uses sherwood oil, ethyl acetate extraction successively, obtain sherwood oil and acetic acid ethyl acetate extract respectively, get acetic acid ethyl acetate extract, decompression and solvent recovery gets the ethyl acetate extract powder;
3. separation and purification
The ethyl acetate extract powder is gone up silica gel decompression column chromatography routinely, with the methylene chloride-methanol system with 50: 1-20: 1-10: 1-5: 1-1: 1 carries out gradient elution, collect 20 parts of elutriants altogether, every part of 2000ml, 12-16 part is merged, go up silica gel decompression column chromatography behind the decompression and solvent recovery once more, with sherwood oil-acetone system with 20: 1-10: 1-5: 1-1: 1 carries out gradient elution, collect 10 parts of elutriants altogether, every part of 2000ml merges 5-7 part, carrying out column chromatography with the open post of anti-phase ODS filler again behind the decompression and solvent recovery separates, use the methanol-water gradient elution, get 60% methanol-water wash-out part respectively, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery, with 70% methanol-water wash-out, separate and obtain compound 1, compound 2, compound 3; Get 70% methanol-water wash-out part, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery,, separate obtaining compound 7 with 75% methanol-water wash-out; Get 80% methanol-water wash-out part, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery,, separate obtaining compound 4, compound 5, compound 6 with 85% methanol-water wash-out.
Embodiment
Now in conjunction with the embodiments, the present invention is described in detail.
Embodiment 1. preparations triterpene compound 1~7 of the present invention
1. prepare the Leaf of Cherokee Rose extract
Get 2 kilograms of Chinese medicine Leaf of Cherokee Rose, with 70% aqueous ethanolic solution soaked overnight of 10 times of volumes, heating and refluxing extraction 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery gets Leaf of Cherokee Rose extract medicinal extract;
2. extraction triterpene compound
Medicinal extract is dissolved in water, uses sherwood oil, ethyl acetate extraction successively, obtain sherwood oil and acetic acid ethyl acetate extract respectively, get acetic acid ethyl acetate extract, decompression and solvent recovery gets the ethyl acetate extract powder;
3. separation and purification
The ethyl acetate extract powder is gone up silica gel decompression column chromatography routinely, with the methylene chloride-methanol system with 50: 1-20: 1-10: 1-5: 1-1: 1 carries out gradient elution, collect 20 parts of elutriants altogether, every part of 2000ml, 12-16 part is merged, go up silica gel decompression column chromatography behind the decompression and solvent recovery once more, with sherwood oil-acetone system with 20: 1-10: 1-5: 1-1: 1 carries out gradient elution, collect 10 parts of elutriants altogether, every part of 2000ml merges 5-7 part, carrying out column chromatography with the open post of anti-phase ODS filler again behind the decompression and solvent recovery separates, use the methanol-water gradient elution, get 60% methanol-water wash-out part respectively, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery, with 65% methanol-water wash-out, separate and obtain compound 1 20mg, compound 2 15mg, compound 3 15mg; Get 70% methanol-water wash-out part, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery, with 75% methanol-water wash-out, separate obtaining compound 7 30mg, get 80% methanol-water wash-out part, carry out the reversed phase high performance liquid phase behind the decompression and solvent recovery, with 85% methanol-water wash-out, separate and obtain compound 4 13mg, compound 5 25mg, compound 6 20mg.
Through the magnetic resonance detection analysis, determine the chemical structure of each compound of the present invention, their physico-chemical property and spectral data are respectively:
Compound 1: white unformed powder, 142~146 ℃ of mp.[α]
D 20+25°(c=0.16,MeOH)。UV (MeOH) λ
Max(log) nm:243 (4.26); IR (KBr)
Max: 3420 (OH), 2937,2837,1712 (C=O), 1634,1384cm
-1HRESIMS, m/z 481.3291[M+Na]
+(calcd forC
29H
46O
4Na, 481.3294);
13C and
1H NMR data see Table 1 and table 2.
Compound 2: white unformed powder, 220~225 ℃ of mp.[α]
D 20-13°(c=0.173,MeOH)。UV (MeOH) λ
Max(log) nm:240 (4.26); IR (KBr)
Max: 3446 (OH), 2925,2873,2832,1636cm
-1HRESIMS, m/z 465.3343[M+Na]
+(calcd for C
29H
46O
3Na, 465.3345);
13C and
1H NMR data see Table 1 and table 2.
Compound 3: white unformed powder, 259~263 ℃ of mp.[α]
D 20+10°(c=0.07,MeOH)。UV (MeOH) λ
Max(log) nm:240 (4.26); IR (KBr)
Max: 3406 (OH), 2935,2868,1701 (C=O), 1458,1384cm
-1HRESIMS, m/z 525.3188[M+Na]
+(calcd forC
30H
46O
6Na, 525.3192);
13C and
1H NMR data see Table 1 and table 2.
Compound 4: white unformed powder, mp 248~252C.[α]
D 18+0°(c=0.08,MeOH)。IR (KBr)
Max: 3421 (OH), 2941,1698 (C=O), 1384cm
-1HRESIMS, m/z 495.3451[M+Na]
+(cacld for C
30H
48O
4Na, 495.3450);
13C and
1H NMR data see Table 1 and table 2.
Compound 5: white unformed powder, 216~220 ℃ of mp.[α]
D 20+24°(c=0.22,MeOH)。IR (KBr)
Max: 3420 (OH), 2940,1695 (C=O), 1384cm
-1HRESIMS, m/z 527.3344[M+Na]
+(calcd for C
30H
48O
6Na, 527.3349);
13C and
1H NMR data see Table 1 and table 2.
Compound 6: white unformed powder, mp 292~295C.[α]
D 20+63°(c=0.085,MeOH)。IR (KBr)
Max: 3420 (OH), 2946,1700 (C=O), 1384cm
-1HRESIMS, m/z 511.3396[M+Na]
+(calcd for C
30H
48O
5Na, 511.3399);
13C and
1H NMR data see Table 1 and table 2.
Compound 7: white unformed powder, 290~294 ℃ of mp.[α]
D 20+3°(c=0.173,CH
2Cl
2)。IR (KBr)
Max: 3425 (OH), 2939,1740 (C=O) cm
-1HRESIMS, m/z 611.3925[M+Na]
+(calcd for C
35H
56O
7Na, 611.3924);
13C and
1H NMR data see Table 1 and table 2.
Table 1. compound 1-7's
13C-NMR spectrum data (pyridine-d
5, 125MHz)
aIn?CDCl
3
Table 2. compound 1-7's
1H-NMR spectrum data (pyridine-d
5, 500MHz)
aIn?CDCl
3
The test of The compounds of this invention anti-inflammatory activity
Adopt the influence of luciferase intensity in 1~7 pair of lipopolysaccharides of compound (LPS) inductive NF-κ B-luc, the 293 Cell Line cells to prove its anti-inflammatory activity.
1. the preparation of drug solution:
1) compound 1~7 being mixed with final concentration with DMSO respectively is 20mg/ml solution, places-4 ℃ of preservations;
2) LPS:L2654 (sigma) uses dH
2It is 100 μ g/ml solution that O is mixed with concentration ,-20 ℃ of preservations.
2. cell strain: use anti-inflammatory drug screening implement cell strain NF-κ B-luc 293 Cell Line, provide by pharmacology teaching and research room of pharmaceutical college of The 2nd Army Medical College.
3. test method:
The recovery cell and the cultivation of going down to posterity routinely, the perfect medium of use DMEM+10%FBS; Get P2 for the logarithmic phase cell, use the method for trysinization to prepare cell suspension, inoculating cell is to 96 porocyte culture plates, and every porocyte suspension is 100 μ l, and cell count is 1 * 10
4Individual; Each compound is divided into 6 groups by every hole different pharmaceutical concentration, and promptly 0 μ g/ml, 12.5 μ g/ml, 25 μ g/ml, 50 μ g/ml, 100 μ g/m and 200 μ g/ml organize, and 5%CO is put in 3 every group multiple holes
2Incubator adds LPS (final concentration is 1 μ g/ml) in 37 ℃ of culturing cells 4 hours, continues to cultivate 48 hours, collects respectively routinely and respectively organizes cell sample, carries out uciferase activity and detects.Whether the detection data to luciferase are carried out statistical study, inhibited for the inflammatory reaction of LPS inductive to determine the medicine pre-treatment.The results are shown in Table 3.
Table 3. compound 1-7 is to luciferase intensity detection (RLU) (mean value ± variance) in LPS (1ug/ml) the inductive NF-κ B-luc 293 Cell Line cells
Annotate: * P<0.05, * * P<0.01; Medicine pretreated group vs model group
By table 3 as seen, in 293 cells, compound 1-7 can obviously suppress the NF-κ B activation that LPS causes, and presents dose-dependence, shows that The compounds of this invention has significant anti-inflammatory activity, therefore, can be used for preparing anti-inflammatory drug.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010179553XA CN101830964B (en) | 2010-05-21 | 2010-05-21 | Triterpenoid compounds with anti-inflammatory activities |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010179553XA CN101830964B (en) | 2010-05-21 | 2010-05-21 | Triterpenoid compounds with anti-inflammatory activities |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101830964A true CN101830964A (en) | 2010-09-15 |
CN101830964B CN101830964B (en) | 2012-05-02 |
Family
ID=42715201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010179553XA Expired - Fee Related CN101830964B (en) | 2010-05-21 | 2010-05-21 | Triterpenoid compounds with anti-inflammatory activities |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101830964B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584929A (en) * | 2011-12-29 | 2012-07-18 | 广西壮族自治区药用植物园 | Extracting and purifying method of cherokee rose root saponin D and E in cherokee rose root |
CN110577562A (en) * | 2019-05-13 | 2019-12-17 | 株洲千金药业股份有限公司 | Triterpenoid and pharmaceutically acceptable salt thereof, and preparation method and application thereof |
CN111303237A (en) * | 2020-03-06 | 2020-06-19 | 上海市闵行区中心医院 | Polyhydroxy-substituted oleanane pentacyclic triterpenoid, preparation method thereof and application thereof in preparing antifungal medicines |
CN112773809A (en) * | 2021-03-22 | 2021-05-11 | 苏州大学 | Application of multinoside in preparing medicine for treating inflammatory bowel disease |
WO2022135331A1 (en) * | 2020-12-21 | 2022-06-30 | 上海凯屹医药科技有限公司 | Stable liquid pharmaceutical composition containing kuding saponin compound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101590134A (en) * | 2009-06-30 | 2009-12-02 | 沈阳药科大学 | Has total triterpene of garden burnet root of anti-inflammatory and analgesic effect and preparation method thereof |
-
2010
- 2010-05-21 CN CN201010179553XA patent/CN101830964B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101590134A (en) * | 2009-06-30 | 2009-12-02 | 沈阳药科大学 | Has total triterpene of garden burnet root of anti-inflammatory and analgesic effect and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
《Phytomedicine》 20020930 Sosa S. 等 Topical anti-inflammatory activity of Bauhinia tarapotensis leaves 646-653 1-2 第9卷, 第7期 2 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584929A (en) * | 2011-12-29 | 2012-07-18 | 广西壮族自治区药用植物园 | Extracting and purifying method of cherokee rose root saponin D and E in cherokee rose root |
CN110577562A (en) * | 2019-05-13 | 2019-12-17 | 株洲千金药业股份有限公司 | Triterpenoid and pharmaceutically acceptable salt thereof, and preparation method and application thereof |
CN111303237A (en) * | 2020-03-06 | 2020-06-19 | 上海市闵行区中心医院 | Polyhydroxy-substituted oleanane pentacyclic triterpenoid, preparation method thereof and application thereof in preparing antifungal medicines |
CN111303237B (en) * | 2020-03-06 | 2022-05-03 | 上海市闵行区中心医院 | Polyhydroxy-substituted oleanane pentacyclic triterpenoid, preparation method thereof and application thereof in preparing antifungal medicines |
WO2022135331A1 (en) * | 2020-12-21 | 2022-06-30 | 上海凯屹医药科技有限公司 | Stable liquid pharmaceutical composition containing kuding saponin compound |
CN112773809A (en) * | 2021-03-22 | 2021-05-11 | 苏州大学 | Application of multinoside in preparing medicine for treating inflammatory bowel disease |
Also Published As
Publication number | Publication date |
---|---|
CN101830964B (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chang et al. | Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia | |
Wang et al. | Cycloartane triterpenoid saponins from water soluble of Passiflora edulis Sims and their antidepressant-like effects | |
CN101830964B (en) | Triterpenoid compounds with anti-inflammatory activities | |
Peng et al. | Antitumor activity of C-21 steroidal glycosides from Cynanchum auriculatum Royle ex Wight | |
Jacinto et al. | Cytotoxic cardenolide and sterols from Calotropis gigantea | |
CN101824067A (en) | Barrigenol-type triterpenoid saponins compound, preparation method and application thereof | |
Xue et al. | Relationship between antimicrobial activity and amphipathic structure of ginsenosides | |
Madikizela et al. | Isolation and characterization of antimicrobial compounds from Terminalia phanerophlebia Engl. & Diels leaf extracts | |
Ma et al. | Six new dammarane-type triterpenes from acidic hydrolysate of the stems-leaves of Panax ginseng and their inhibitory–activities against three human cancer cell lines | |
Tripathee et al. | An assessment of ethnomedicinal use, chemical constituents analysis and bioactivity evaluation on high altitude medicinal plant Delphinium brunonianum of Manang district | |
CN103012537B (en) | Dammarane type triterpene compound and preparation method and application thereof | |
CN101899082A (en) | Triterpenoid saponin compound, application and preparation method | |
CN103304618A (en) | Triterpenoid saponin compound with anti-inflammatory activity as well as preparation method and application thereof | |
CN102942605B (en) | The preparation method of iridoid and application thereof in Jasminum lanceolarium Roxb. | |
CN105061545B (en) | Triterpene saponin componds and its preparation method and application in shiny-leaved yellowhorn | |
Zhou et al. | Two novel saponins of 20, 26-epoxy derivatives of pseudojujubogenin from the seeds of Hovenia trichocarpa | |
CN101880306A (en) | Stauntonia brachyanthera Hand-Mazz saponins components as well as preparation method and application thereof | |
CN105198943B (en) | A kind of entitled tea hill how glycosides A acylated flavonoids glucosides and its preparation method and application | |
CN106317156A (en) | Pentahydroxy diketone cucurbitane type triterpene as well as preparation method and application thereof | |
CN114702467B (en) | Aromatic cassane diterpenoid compound of golden pineapple, extraction method and application | |
CN111018877A (en) | Sesquiterpene derivative in elecampane inula root, preparation method and application thereof | |
CN103864876B (en) | Xylocarpus granatum element in heptan and its production and use | |
CN102267891A (en) | Novel triterpenoid compound and preparation method thereof | |
CN112898357B (en) | Diterpene glycoside novel compound in trollius chinensis bunge and separation and purification method and application thereof | |
CN105330588B (en) | Alkaloid Oleracone and its extraction separation method in purslane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120502 Termination date: 20150521 |
|
EXPY | Termination of patent right or utility model |